We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Randox Laboratories

  Platinum Provides global diagnostic solutions for hospital laboratories, forensic laboratories, research laboratories, pharmac... read more Featured Products: More products

Download Mobile App





Randox Leads UK’s International Travel Testing Efforts in Response to New Omicron Variant

By LabMedica International staff writers
Posted on 02 Dec 2021
Print article
Image: Randox Leads UK’s International Travel Testing Efforts in Response to New Omicron Variant (Photo courtesy of Randox Laboratories)
Image: Randox Leads UK’s International Travel Testing Efforts in Response to New Omicron Variant (Photo courtesy of Randox Laboratories)

Randox Laboratories (Crumlin, UK) is leading the UK’s effort to expand PCR testing to support international travel in response to the emergence of the Omicron variant of COVID-19.

The outbreak of Omicron prompted the UK government to announce late on Saturday 27th November that it would stop accepting lateral flow tests as valid entry for international arrivals from Tuesday 30th November. The unexpected move has put pressure on the diagnostics industry to rapidly boost PCR testing efforts to ensure as little disruption as possible to international travel prior to and during the Christmas break. Randox has responded within 48 hours by returning international travel PCR capacity within its laboratories to 180,000 tests per day, with a potential to increase the number further. It has also immediately invested an additional GBP 10 million in consumable materials to enable high volume Day 2 PCR testing with next-day results.

Since the start of the pandemic, Randox has built, equipped and staffed over 80,000 square feet of PCR laboratories. In addition to its Northern Ireland facilities, it has opened further PCR laboratories in Manchester and Greater London and added 1,000 additional staff to support high volume PCR testing 24 hours a day, seven days a week, 365 days a year. Randox has processed over 21 million PCR tests to date, including more than 15 million for the UK’s National Testing Programme, and is the only laboratory in the UK to have processed over 100,000 PCR tests in a single day.

“Our 40 years of experience in testing and diagnostics have enabled us to rise to the challenges presented by this national and global crisis. We are proud to continue to provide an efficient service that represents value for money for both the National Testing Programme and the travelling public,” said a Randox spokesperson. “Having expanded our overall workforce in the face of this pandemic to over 3,300 we are well-placed to rapidly redeploy staff in response to the government’s fast decision to switch to PCR testing only for international travelers. These staff redeployments facilitate both laboratory testing and the high-volume preparation and dispatch of the critical sample collection kits that are essential to our service. We currently have a capacity for international travel of 180,000 PCR tests per day and we are confident we will be able to keep pace with demand for these essential tests.”

Related Links:
Randox Laboratories 

Gold Supplier
Fluorimetric Immunoassay Analyzer
Confiscope F20
New
Automated Nucleic Acid Extraction & Purification System
ExiPrep16 Dx
New
Electrolyte Analyzer
EXIAS
New
Immunodiagnostic Analyzer
LiCA 5000

Print article
IIR Middle East

Channels

Molecular Diagnostics

view channel
Illustration

Point-of-Care Lateral Flow Test Detects Bladder Cancer Using Urine Sample within Minutes

A breakthrough diagnostics platform uses a multiplexed lateral flow assay that detects 10 bladder cancer biomarkers from a urine sample in either laboratory or point-of-care settings. SCIENION (Berlin,... Read more

Hematology

view channel
Image: Bone marrow aspirate from a patient with Acute Myeloid Leukemia: Blasts are the predominant population and have a high nuclear to cytoplasmic ratio and generally lack granules. (Photo courtesy of Professor Peter G. Maslak, MD)

Cord Blood and Matched Related Donor Transplantation Compared in Acute Myeloid Leukemia

The prognosis of primary refractory and relapsed acute myeloid leukemia is poor, with a five-year overall survival of less than 10%. Allogeneic hematopoietic stem cell transplantation (HSCT) is the only... Read more

Industry

view channel
Illustration

Global Immunofluorescence Assay (IFA) Market to Surpass USD 4 Billion by 2028 Due to Growing Burden of Infectious Diseases

The global immunofluorescence assay (IFA) market is expected to reach USD 4.01 billion by 2028, driven by the increasing global healthcare burden of chronic and infectious diseases, rising application... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.